Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Ultrasound‐Guided Fasciotomies of the Deep and Superficial Posterior Leg Compartments for Chronic Exertional Compartment Syndrome: A Cadaveric Investigation
Reisner, Jacob H. , Noble-Taylor, Kayle Elizabeth, Cummings, Nancy M. , Lachman, Nirusha , Noble-Taylor, Kayle E., Finnoff, Jonathan T.

Mayo Clinic

PM&R | August 26, 2020 | Volume: 13 | Issue: 8 | Pages: 862-869

10.1002/pmrj.12477 | PMID 32844578 Get It

BackgroundChronic exertional compartment syndrome (CECS) is a type of leg pain related to elevated intracompartmental pressure with activity in one or more of the four compartments of the leg. Open fasciotomy is the definitive treatment for CECS but has a reported complication rate of up to 15.7% and return to full activity reported up to 16 weeks. Ultrasound‐guided (USG) fasciotomy of the anterior and lateral compartments has been translated into clinical practice.ObjectiveTo determine the safety and feasibility of a USG fasciotomy of the deep posterior compartment (DPC) and superficial compartment (SPC) of the leg in a fresh‐frozen cadaveric model.DesignProspective, cadaveric laboratory investigation.SettingProcedural skills laboratory at an academic institution.Cadaveric CohortTen fresh‐frozen cadaveric knee‐ankle‐foot specimens from five female and five male donors aged 58 to 93 years (mean 77.4 years) with body mass indexes of 18.1 to 33.5 kg/m2 (mean 25.1 kg/m2).Methods or InterventionsOne experienced operator performed 10 USG DPC and SPC fasciotomies. A clinical anatomist performed dissections of each.Main Outcome MeasuresAchievement of target length and continuity of release was recorded. Target lengths of 10 cm for the superficial posterior compartment (SPC) and 15 cm for the deep posterior compartment (DPC) were established based on previous studies. Tendinous and neurovascular structures were assessed for damage.ResultsNo tendon or neurovascular injuries were observed. In the SPC, target length was achieved in 90% and continuous release was observed in 80%. In the DPC, target length was achieved in 60% and continuity observed in 30%.ConclusionsThese findings suggest that SPC USG fasciotomies using the technique described in this study are feasible, may be safe, and warrant further translational research; however, DPC USG fasciotomies are more challenging and require more technical refinement prior to clinical translation.
First analysis of an international pediatric melanoma and atypical melanocytic neoplasm database
Averbook, Bruce J., Jukic, D.M., Delman, Keith A. , Pittelkow, Mark R. , Rao, Jia‐Sheng , Panneerselvam, A., Zager, Jonathan S. , Sabel, Michael S. , Swetter, Susan M. , Kirkwood, John M.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 9013-9013

10.1200/jco.2009.27.15_suppl.9013 Get It

9013 Background: Pediatric melanoma (PM) care has been extrapolated from adult melanoma data. PM and atypical melanocytic neoplasms (AMNs) appear to have different biology. An international database (DB) was developed to clarify their behavior. Methods: IRB approval was obtained at 12 institutions. An SQL-DB was developed for web entry of de-identified demographic and pathologic data for PM and AMN patients (pts) < 21yr through an honest broker system at the University of Pittsburgh. Institutions retained a key of pts entered with assigned numbers for quality assurance and updates. Statistical analysis used Kaplan-Meier survival curves, univariate linear trends and log rank tests. In situ melanoma was excluded from PM survival analysis. Results: 828 pts were registered as of 31 Oct 2008 (ages 11mo-23; median 15yr). 34 pts 21–23yr entered were left in the DB for statistical comparison. Diagnosis years ranged from 1936–2008. 455 pts had complete follow-up. Too few AMN pts had complete follow-up for analysis (18/208). After excluding 32 in situ and 40 with other incomplete data, 365 PM out of 415 total PM were evaluable for OS and 351 for DFS (Stage IV removed). Mean/median age for evaluable PM pts was 16.44/17-yrs (range 1–21yr). 591 pts were age 10–20 while 203 were < 10. Sentinel lymph node (SLN) biopsy showed spread in 30.1 % PM pts (compared to 50% [4/8] of AMN SLN pts). 10-yr PM OS was 80.6%, and pts 0–10 yr had 100% 10-yr OS compared to 69.6% for pts age 10–15 and 79.49% for age 15–20 (p= 0.1473). OS did not differ significantly by gender. Stage predicted OS (p<0.0001). 10-yr OS was 94.13% for Stage I (n=174), 79.62% for stage II (n=67) & 77.14% for stage III (n=75). Thickness affected 10-yr OS: 0–1mm=97% (n=147), 1.1–2mm 70% (n=84), 2.01–4mm 78% (n=71) & >4mm 81% (n=25), p= 0.0099. Survival was similar for pts with PM > 1mm of the several T stage groupings. Ulceration adversely affected OS (p=0.022). Mitosis, defined as present/absent did not alter survival. Nodal metastasis correlated with worse OS (p= 0.170). Conclusions: Stage, thickness, ulceration, and nodal status are significant predictors of OS for PM. Further study will focus on multivariable analysis of PM and AMNs after updating pts, increasing accrual, and cleaning data. No significant financial relationships to disclose.
Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003)
Reeder, Craig B. , Buckstein, Rena , Bouabdallah, Réda, Polikoff, Jonathan, Pietronigro, Dennis, Czuczman, M. S., Witzig, Thomas E. , Zinzani, Pier Luigi , Vose, Julie M. , Haïoun, Corinne

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 8569-8569

10.1200/jco.2009.27.15_suppl.8569 Get It

8569 Introduction: Relapsed or refractory MCL patients demonstrated a promising overall response rate (ORR) of 53% with a median duration of response (DR) of 13.7 months to single-agent lenalidomide when analyzed as a subset in a recent a phase II study (NHL-002). A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL. In this report, we analyze the current results from the MCL patients enrolled in this trial. Methods: Patients with relapsed or refractory MCL and measurable disease 2 cm after at least 1 prior treatment regimen were eligible. Patients received 25 mg of lenalidomide orally once daily on days 1–21 of every 28-day cycle. Patients continued therapy until disease progression or toxicity. The 1999 IWLRC methodology was used to assess response and progression. Results: Fifty-four MCL patients were enrolled and were evaluable for response assessment. Median age was 69 years (33–82) and 40 patients (74%) were male. Median time from diagnosis was 3.2 years (0.4–10.4), patients had received a median of 3 prior treatments (1–8), 17 of the patients (32%) had received prior bortezomib therapy (MCL-bortezomib), and 14 (26%) had received a prior stem cell transplant (MCL-stem cell). Response rates are shown in the Table. The most common grade 3 or 4 adverse events were neutropenia (43%), thrombocytopenia (22%) and anemia (11%). Conclusions: This is the second study to demonstrate that lenalidomide oral monotherapy is effective in the treatment of patients with relapsed or refractory MCL, with manageable side effects. [Table: see text] [Table: see text]
Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003)
Czuczman, M. S., Reeder, Craig B. , Buckstein, Rena , Bouabdallah, Réda, Polikoff, Jonathan, Ervin‐Haynes, Annette, Witzig, T. E., Vose, Julie M. , Zinzani, Pier Luigi , Haïoun, Corinne

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: e19504-e19504

10.1200/jco.2009.27.15_suppl.e19504 Get It

e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis. A recent phase II trial (NHL-002) of lenalidomide in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) demonstrated a 19% overall response rate (ORR) with a 7-month median duration of response (DR) in the subset of patients with DLBCL. A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL that had received at least one prior treatment and had measurable disease. Herein, we report the data from the DLBCL patients enrolled in this trial. Methods: Patients received 25 mg oral lenalidomide once daily on days 1–21 of every 28-day cycle and continued therapy until disease progression or toxicity. The 1999 IWLRC methodology was used to assess response and progression. Results: One hundred-three DLBCL patients were enrolled and were evaluable for response assessment. The median age was 66 years (21–87) and 70 patients (68%) were male. Median time from diagnosis was 2 years (0.4–18.6), patients had received a median of 3 prior treatment regimens (1–10) and 46 of the patients (45%) had received a prior stem cell transplant (DLBCL-stem cell). Response rates are shown in the Table . Grade 3 or 4 adverse events occurring in more than 5% of patients were neutropenia (34%), thrombocytopenia (18%), asthenia (9%), anemia (8%), leucopenia (7%), back pain (6%) and dyspnea (6%). Conclusions: This international study demonstrates that lenalidomide is active in heavily pre-treated patients with relapsed or refractory DLBCL and has manageable side effects. [Table: see text] [Table: see text]
Diffuse Pulmonary Ossification on High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis, Systemic Sclerosis-Related Interstitial Lung Disease, and Chronic Hypersensitivity Pneumonitis: A Comparative Study
Walkoff, Lara , Dixit, Anuj , Ryu, Jay H. , Cox, Christian W. , Ryu, Jay H , Chung, Jonathan Hero

Mayo Clinic

Journal of Computer Assisted Tomography | August 25, 2020 | Volume: 44 | Issue: 5 | Pages: 667-672

10.1097/rct.0000000000001076 | PMID 32842066 Get It

Objective The aim of the study was to compare the prevalence of diffuse pulmonary ossification (DPO) in idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc)-related interstitial lung disease (ILD), and chronic hypersensitivity pneumonitis (HP). Methods High-resolution computed tomography (HRCT) from 71 IPF, 67 SSc-ILD, and 75 HP cases were independently evaluated by 2 thoracic radiologists blinded to patient data. Studies were assessed for the presence of DPO, HRCT scanning pattern, stigmata of granulomatous infection, and honeycombing. Results The prevalence of DPO was significantly higher in cases of IPF and SSc compared with HP, although there was no significant difference in prevalence between the IPF and SSc groups, even when accounting for the presence of prior granulomatous infection. Interobserver agreement for the presence of DPO was substantial. Conclusions Although prevalence DPO on HRCT varies between some forms of ILD, the use of DPO to influence characterization of ILD should be considered with caution.
Letter: An International Investigation Into the COVID-19 Pandemic and Workforce Depletion in Highly Specialized Neurointerventional Units – Insights From Stroke Thrombectomy and Aneurysm Registry and Endovascular Neurosurgery Research Group
Alawieh, Ali , Kasab, Sami Al , Almallouhi, Eyad , Levitt, Michael R. , Jabbour, Pascal , Sweid, Ahmad , Starke, Robert M. , Wolfe, Stacey Q , Fragata, Isabel , Maier, Ilko , Matouk, Charles, Howard, Brian M. , Grossberg, Jonathan A , Cawley, M. F., Kan, Peter , Hafeez, Muhammad Ubaid , Singer, Justin, Crowley, R. Webster , Joshi, Krishna C. , Brinjikji, Waleed , Ogilvy, Christopher S. , Gomez‐Paz, Santiago , Veznedaroglu, Erol, Binning, Mandy J., Soomro, Jazba , Williamson, Richard , Chalhoub, Reda , Crosa, Roberto , Webb, Sharon, Psychogios, Marios, Ducruet, Andrew F. , Albuquerque, Felipe C. , Turner, Raymond, Casagrande, Walter, Leacy, Reade De , Fessler, Richard D., Osanai, Toshiya , Chowdhry, Shakeel , Schirmer, Clemens M. , Ringer, Andrew J. , Spiotta, Alejandro M , collaborators, STAR and ENRG, Savastano, Luis E., Gomez-Paz, Santiago , Crosa, Roberto , Levitt, Michael R , De Leacy, Reade , Schirmer, Clemens M , Almallouhi, Eyad , Hafeez, Muhammad U , Wolfe, Stacey Quintero , Fragata, Isabel , Howard, Brian M , Alawieh, Ali M , Ogilvy, Christopher S , Jabbour, Pascal , Saini, Vasu A , Fargen, Kyle M , Arthur, Adam Stephen , Goyal, Nitin , Cawley, Michael, Savastano, Luis , Levy, Elad I. , Waqas, Muhammad, Mokin, Maxim , Mascitelli, Justin R , Yoo, Albert J. , Grande, Andrew Walker , Psychogios, Marios‐Nikos , Majmundar, Neil J. , Al‐Mufti, Fawaz , Mocco, J , Park, Minhee , collaborators, STAR and ENRG

Mayo Clinic

Neurosurgery | August 24, 2020 | Volume: 87 | Issue: 6 | Pages: E697-E699

10.1093/neuros/nyaa415 | PMID 32893855 Get It

Stereotactic Radiosurgery With Versus Without Embolization for Brain Arteriovenous Malformations
Ding, Dale , Lee, Cheng‐Chia , Kearns, Kathryn N. , Pomeraniec, I. Jonathan , Cifarelli, Christopher P. , Arsanious, David, Liščák, Roman , Hanuška, Jaromír, Woo, Shiao Y. , Ironside, Natasha , Warnick, Ronald E. , Mathieu, David , Mureb, Monica , Benjamin, Carolina , Feliciano, Caleb , Rodríguez‐Mercado, Rafael, Cockroft, Kevin M. , Simon, Scott D. , Mackley, Heath B., Zammar, Samer G. , Patel, Neel, Padmanaban, Varun , Beatson, Nathan, Saylany, Anissa , Lee, John, Sheehan, Jason P. , May, Jaromír , Ding, Dale , Mathieu, David , Chen, Ching‐Jen , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Kondziolka, Douglas , Lee, John

Mayo Clinic

Neurosurgery | August 23, 2020 | Volume: 88 | Issue: 2 | Pages: 313-321

10.1093/neuros/nyaa418 | PMID 33017465 Get It

Abstract BACKGROUND Prior comparisons of brain arteriovenous malformations (AVMs) treated using stereotactic radiosurgery (SRS) with or without embolization were inherently flawed, due to differences in the pretreatment nidus volumes. OBJECTIVE To compare the outcomes of embolization and SRS, vs SRS alone for AVMs using pre-embolization malformation features. METHODS We retrospectively reviewed International Radiosurgery Research Foundation AVM databases from 1987 to 2018. Patients were categorized into the embolization and SRS (E + SRS) or SRS alone (SRS-only) cohorts. The 2 cohorts were matched in a 1:1 ratio using propensity scores. Primary outcome was defined as AVM obliteration. Secondary outcomes were post-SRS hemorrhage, all-cause mortality, radiologic and symptomatic radiation-induced changes (RIC), and cyst formation. RESULTS The matched cohorts each comprised 101 patients. Crude AVM obliteration rates were similar between the matched E + SRS vs SRS-only cohorts (48.5% vs 54.5%; odds ratio = 0.788, P = .399). Cumulative probabilities of obliteration at 3, 4, 5, and 6 yr were also similar between the E + SRS (33.0%, 46.4%, 56.2%, and 60.8%, respectively) and SRS-only (32.9%, 46.2%, 56.0%, and 60.6%, respectively) cohorts (subhazard ratio (SHR) = 1.005, P = .981). Cumulative probabilities of radiologic RIC at 3, 4, 5, and 6 yr were lower in the E + SRS (25.0%, 25.7%, 26.7%, and 26.7%, respectively) vs SRS-only (45.3%, 46.2%, 47.8%, and 47.8%, respectively) cohort (SHR = 0.478, P = .004). Symptomatic and asymptomatic embolization-related complication rates were 8.3% and 18.6%, respectively. Rates of post-SRS hemorrhage, all-cause mortality, symptomatic RIC, and cyst formation were similar between the matched cohorts. CONCLUSION This study refutes the prevalent notion that AVM embolization negatively affects the likelihood of obliteration after SRS.
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Parikh, Neehar D. , Roberts, Lewis R. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Valle, Juan W. , Valle, Juan W , Roberts, Lewis R , Parikh, Neehar D , Bridgewater, John , Roberts, Rebecca, Salem, Riad , Sicklick, Jason Keith

Mayo Clinic

Cancers | August 21, 2020 | Volume: 12 | Issue: 9 | Pages: 2375

10.3390/cancers12092375 | PMID 32825784 Get It

Background: Patients with cholangiocarcinoma often have indwelling biliary stents or catheters which are prone to obstructions and/or infections; studies show that 20–40% present with fever and/or jaundice requiring urgent treatment in the outpatient setting for which there are no uniform guidelines. The goal was to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: Thirteen expert physicians from relevant specialties, geography, and practice settings were recruited for the panel. Patient scenarios were developed and panelists rated the therapies before and after a face-to-face discussion. The appropriateness of various therapies was rated on a scale from 1–9 and classified as appropriate, inappropriate, or uncertain. Scenarios with greater than 2 (>2) ratings of 1–3 (inappropriate) and greater than 2 (>2) ratings of 7–9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions and the UK (8%) and had practiced for a mean 16.5 years (4–33 years). Panelists rated 480 scenarios before the meeting and re-rated 288 of the clinical scenarios after the meeting. The panelists agreed that ongoing treatment with chemotherapy did not influence decision-making and, therefore, 192 scenarios were excluded from the final list. Disagreement decreased from 37.5% before to 10.4% after the meeting. Consensus on stent/tube manipulation and inpatient antibiotic therapy was obtained and summarized in patients as “appropriate” or “maybe appropriate” based on a patient’s bilirubin level at presentation. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in the urgent management of ascending cholangitis in patients with cholangiocarcinoma.
Overview of HF10 Spinal Cord Stimulation for the Treatment of Chronic Pain and an Introduction to the Senza Omnia™ System
Hagedorn, Jonathan M. , Layno‐Moses, Annie, Sanders, Daniel T., Pak, Daniel , Bailey-Classen, Ashley , Sowder, Timothy, Hagedorn, Jonathan M

Mayo Clinic

Pain Management | August 18, 2020 | Volume: 10 | Issue: 6 | Pages: 367-376

10.2217/pmt-2020-0047 | PMID 32808874 Get It